Diamyd Medical AB (FRA:DMN) Momentum Rank: 2 (As of Sep. 13, 2026) — 71% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:DMN Diamyd Medical AB FRA:DMN
38 GF Score
Price €0.07
GF Value €0.07
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Diamyd Medical AB Momentum Rank?

Diamyd Medical AB FRA:DMN 38 Momentum Rank is 2 as of Sep. 13, 2026, which is 71% below its 10-year median of 7.00. GuruFocus rates FRA:DMN with a GF Score™ of 38/100 and a GF Value™ of €0.07 (Fairly Valued). The stock has 3 warning signs investors should review.

Diamyd Medical AB has the Momentum Rank of 2.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Diamyd Medical AB Momentum Rank Related Terms

FRA:DMN vs VRTX, REGN, MRNA: Momentum Rank Comparison

For the Biotechnology subindustry, Diamyd Medical AB's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diamyd Medical AB Momentum Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's Momentum Rank falls into.


FRA:DMN
38GF Score
Diamyd Medical AB FRA:DMN
Momentum Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Momentum Rank →
What does a Momentum Rank of 2 mean?
Diamyd Medical AB (FRA:DMN) has a Momentum Rank of 2 as of Sep. 13, 2026. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Diamyd Medical AB and its competitors. This is 71% below median its historical median of 7.00. Over the past decade, Diamyd Medical AB's Momentum Rank has ranged from 1.00 to 10.00.
Is Diamyd Medical AB's Momentum Rank too high?
Diamyd Medical AB's current Momentum Rank of 2 is 71% below median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Diamyd Medical AB has a GF Score™ of 38/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Diamyd Medical AB's Momentum Rank compare to VRTX and REGN?
Diamyd Medical AB's Momentum Rank of 2 can be compared against companies in the Biotechnology industry. Historically, Diamyd Medical AB's own Momentum Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Momentum Rank for a Biotechnology company?
A good Momentum Rank depends on the Biotechnology industry context. However, Momentum Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Momentum Rank mean?
A high Momentum Rank can signal that a stock is expensive relative to its fundamentals. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Diamyd Medical AB and its competitors. Diamyd Medical AB's current Momentum Rank is 2, which is 71% below median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamyd Medical AB stock overvalued right now?
Based on GuruFocus' analysis, Diamyd Medical AB (FRA:DMN) is currently considered Fairly Valued. The stock's GF Value™ is €0.07, compared to a current price of €0.07 — trading 1.3% below its estimated fair value. The current Momentum Rank is 2, which is 71% below median its 10-year median of 7.00. Diamyd Medical AB's overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Momentum Rank calculated?
Momentum Rank is calculated from a company's financial statements. For Diamyd Medical AB (FRA:DMN), the current Momentum Rank is 2 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diamyd Medical AB (FRA:DMN) Overvalued in 2026?

Based on GuruFocus' analysis, Diamyd Medical AB stock appears to be undervalued. The current stock price of €0.07 is trading 1.3% below its estimated GF Value™ of €0.07. GuruFocus considers Diamyd Medical AB to be Fairly Valued.

Key valuation signals for FRA:DMN:

  • Momentum Rank: 2 (71% below median its 10-year median of 7.00)
  • GF Value™: €0.07 vs. price of €0.07 (1.3% below fair value)
  • GF Score™: 38/100 with 3 warning signs

No single metric tells the full story. See the FRA:DMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diamyd Medical AB Business Description

Other Exchanges DMYD B:Sweden
Address Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
38GF Score

Get the complete analysis for FRA:DMN

Momentum Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.07
Price
€0.07
GF Value